EZH2 and ovarian cancer: Pharmacological EZH2 inhibition in vivo also led to increased levels of tumor-producing pro-Th1 chemokines and enhanced recruitment of effector T cells, resulting in reduced tumor volume and prolonged survival time in human ovarian cancers (51, 52).